COGNITION THERAPEUTICS INC. - COMMON STOCK

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

07 май 2024 07:30:00 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

29 апр 2024 07:30:57 Источник Nasdaq GlobeNewswire

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease

22 апр 2024 07:30:22 Источник Nasdaq GlobeNewswire

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

02 апр 2024 07:30:47 Источник Nasdaq GlobeNewswire

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024

01 апр 2024 07:30:39 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

26 мар 2024 07:00:56 Источник Nasdaq GlobeNewswire

Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

15 мар 2024 07:30:59 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock

14 мар 2024 16:05:15 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock

11 мар 2024 20:16:05 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Announces Proposed Public Offering of Common Stock

11 мар 2024 16:05:16 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies

06 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire

Cognition Therapeutics to Present at the TD Cowen Health Care Conference

26 фев 2024 07:30:59 Источник Nasdaq GlobeNewswire

New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812

06 фев 2024 08:47:22 Источник Nasdaq GlobeNewswire

Cognition Therapeutics CEO Issues Letter to Shareholders

04 янв 2024 07:30:00 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens

16 ноя 2023 07:30:35 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases

15 ноя 2023 07:30:48 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

07 ноя 2023 07:30:25 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

02 ноя 2023 07:30:00 Источник Nasdaq GlobeNewswire

Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD

27 окт 2023 07:30:15 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD

24 окт 2023 16:30:41 Источник Nasdaq GlobeNewswire